{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:19:51Z","timestamp":1785766791769,"version":"3.56.0"},"reference-count":39,"publisher":"American Veterinary Medical Association (AVMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>Objective<\/jats:bold>\u2014To determine the pharmacokinetics of voriconazole following IV and PO administration and assess the distribution of voriconazole into body fluids following repeated PO administration in horses.<\/jats:p>\n<jats:p><jats:bold>Animals<\/jats:bold>\u20146 clinically normal adult horses.<\/jats:p>\n<jats:p><jats:bold>Procedures<\/jats:bold>\u2014All horses received voriconazole (10 mg\/kg) IV and PO (2-week interval between treatments). Plasma voriconazole concentrations were determined prior to and at intervals following administration. Subsequently, voriconazole was administered PO (3 mg\/kg) twice daily for 10 days to all horses; plasma, synovial fluid, CSF, urine, and preocular tear film concentrations of voriconazole were then assessed.<\/jats:p>\n<jats:p><jats:bold>Results<\/jats:bold>\u2014Mean \u00b1 SD volume of distribution at steady state was 1,604.9 \u00b1 406.4 mL\/kg. Systemic bioavailability of voriconazole following PO administration was 95 \u00b1 19%; the highest plasma concentration of 6.1 \u00b1 1.4 \u03bcg\/mL was attained at 0.6 to 2.3 hours. Mean peak plasma concentration was 2.57 \u03bcg\/mL, and mean trough plasma concentration was 1.32 \u03bcg\/mL. Mean plasma, CSF, synovial fluid, urine, and preocular tear film concentrations of voriconazole after long-term PO administration were 5.163 \u00b1 1.594 \u03bcg\/mL, 2.508 \u00b1 1.616 \u03bcg\/mL, 3.073 \u00b1 2.093 \u03bcg\/mL, 4.422 \u00b1 0.8095 \u03bcg\/mL, and 3.376 \u00b1 1.297 \u03bcg\/mL, respectively.<\/jats:p>\n<jats:p><jats:bold>Conclusions and Clinical Relevance<\/jats:bold>\u2014Results indicated that voriconazole distributed quickly and widely in the body; following a single IV dose, initial plasma concentrations were high with a steady and early decrease in plasma concentration. Absorption of voriconazole after PO administration was excellent, compared with absorption after IV administration. Voriconazole appears to be another option for the treatment of fungal infections in horses.<\/jats:p>","DOI":"10.2460\/ajvr.68.10.1115","type":"journal-article","created":{"date-parts":[[2008,3,21]],"date-time":"2008-03-21T17:39:46Z","timestamp":1206121186000},"page":"1115-1121","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacokinetics of voriconazole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses"],"prefix":"10.2460","volume":"68","author":[{"given":"Carmen M. H.","family":"Colitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico G.","family":"Latimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genneth J.","family":"Pennick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"Equine internal medicine","first-page":"61","article-title":"Bacterial and mycotic infections","author":"Kowalski","year":"1998"},{"key":"ref2","series-title":"Equine internal medicine","first-page":"513","article-title":"Diseases of the skin","author":"Moriello","year":"1997"},{"key":"ref3","series-title":"J Am Vet Med Assoc","first-page":"808","article-title":"Pulmonary aspergillosis in horses: 29 cases (1974\u20131997)","volume":"214","author":"Sweeney","year":"1999"},{"key":"ref4","series-title":"Current therapy in equine medicine","first-page":"193","article-title":"Fungal abortion","author":"Denis","year":"1997"},{"key":"ref5","series-title":"Large animal internal medicine","first-page":"962","article-title":"Diseases of the renal system","author":"Divers","year":"1996"},{"key":"ref6","series-title":"Equine Vet J","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.2042-3306.1987.tb02649.x","article-title":"Outcome of treatment in 35 cases of guttural pouch mycosis","volume":"19","author":"Greet","year":"1987"},{"key":"ref7","series-title":"Equine ophthalmology","first-page":"157","article-title":"Diseases of the cornea and sclera","author":"Andrew","year":"2005"},{"key":"ref8","series-title":"Equine Vet Educ","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.2042-3292.1992.tb01538.x","article-title":"A review of ten cases of equine mycotic rhinitis","volume":"4","author":"Lawson","year":"1992"},{"key":"ref9","series-title":"Am J Vet Res","first-page":"1606","article-title":"Fluconazole pharmacokinetics in adult horses following intravenous and oral administration and body fluid concentrations following repeated oral dosing","volume":"62","author":"Latimer","year":"2000"},{"key":"ref10","series-title":"Am J Vet Res","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.2460\/ajvr.2005.66.1694","article-title":"Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses","volume":"66","author":"Davis","year":"2005"},{"key":"ref11","series-title":"J Am Vet Med Assoc","first-page":"199","article-title":"Evaluation of itraconazole-dimethyl sulfoxide ointment for treatment of keratomycosis in nine horses","volume":"211","author":"Ball","year":"1997"},{"key":"ref12","series-title":"J Vet Pharmacol Ther","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1046\/j.1365-2885.1997.00822.x","article-title":"Corneal concentrations and preliminary toxicological evaluation of an itraconazole\/dimethyl sulphoxide ophthalmic ointment","volume":"20","author":"Ball","year":"1997"},{"key":"ref13","series-title":"Am J Vet Res","first-page":"316","article-title":"Evaluation of activity of selected ophthalmic antimicrobial agents in combination against common ocular microorganisms","volume":"60","author":"Hinkle","year":"1999"},{"key":"ref14","series-title":"Equine Vet J","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.2042-3306.1998.tb04469.x","article-title":"Equine ulcerative keratomycosis: visual outcome and ocular survival in 39 cases (1987\u20131996)","volume":"30","author":"Andrew","year":"1998"},{"key":"ref15","series-title":"J Am Vet Med Assoc","first-page":"338","article-title":"Amphotericin B treatment of Candida arthritis in two horses","volume":"206","author":"Madison","year":"1995"},{"key":"ref16","series-title":"Equine Vet J","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.2042-3306.1989.tb02148.x","article-title":"Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage","volume":"21","author":"Prades","year":"1989"},{"key":"ref17","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1056\/NEJM199401273300407","article-title":"Oral azole antifungal drugs as systemic antifungal therapy","volume":"330","author":"Como","year":"1994"},{"key":"ref18","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1939-1676.1992.tb00365.x","article-title":"Treatment of coccidioidomycosis osteomyelitis with itraconazole in a horse","volume":"6","author":"Foley","year":"1992"},{"key":"ref19","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1939-1676.1994.tb03221.x","article-title":"Treatment of mycotic rhinitis with itraconazole in three horses","volume":"8","author":"Korenek","year":"1994"},{"key":"ref20","series-title":"Vet Ophthalmol","article-title":"Pharmacokinetics of fluconazole following intravenous and oral administration and ocular tissue and body fluid concentrations of fluconazole following repeated oral dosing in horses","volume":"4","author":"Latimer","year":"2001"},{"key":"ref21","series-title":"Pharmacotherapy","doi-asserted-by":"publisher","first-page":"165S","DOI":"10.1592\/phco.21.12.165S.34509","article-title":"Investigational antifungal agents","volume":"21","author":"Ernst","year":"2001"},{"key":"ref22","series-title":"Curr Opin Infect Dis","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/00001432-200012000-00001","article-title":"Current and future approaches to antifungal therapy","volume":"13","author":"Patterson","year":"2000"},{"key":"ref23","series-title":"Eur J Clin Microbiol Infect Dis","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10096-003-0934-2","article-title":"Two cases of cerebral aspergillosis successfully treated with voriconazole","volume":"22","author":"de Lastours","year":"2003"},{"key":"ref24","series-title":"Support Care Cancer","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00520-003-0523-z","article-title":"Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience","volume":"11","author":"Cesaro","year":"2003"},{"key":"ref25","series-title":"Clin Ther","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0149-2918(03)80126-1","article-title":"Voriconazole","volume":"25","author":"Jeu","year":"2003"},{"key":"ref26","series-title":"Am J Ophthalmol","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ajo.2005.03.030","article-title":"Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with caspofungin","volume":"140","author":"Durand","year":"2005"},{"key":"ref27","series-title":"J Antimicrob Chemother","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/jac\/dkl016","article-title":"Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy","volume":"57","author":"Sagnelli","year":"2006"},{"key":"ref28","series-title":"CNS Drugs","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00023210-200721040-00004","article-title":"Fungal infections of the CNS: treatment strategies for the immunocompromised patient","volume":"21","author":"Black","year":"2007"},{"key":"ref29","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"573","article-title":"In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species","volume":"17","author":"Clancy","year":"1998"},{"key":"ref30","series-title":"Am J Vet Res","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.2460\/ajvr.67.6.1070","article-title":"Pharmacokinetics of voriconazole after oral and intravenous administration to horses","volume":"67","author":"Davis","year":"2006"},{"key":"ref31","series-title":"Am J Vet Res","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2460\/ajvr.67.2.296","article-title":"Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses","volume":"67","author":"Clode","year":"2006"},{"key":"ref32","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1128\/AAC.47.7.2348-2350.2003","article-title":"Development and validation of a high-performance liquid chromatography assay for voriconazole","volume":"47","author":"Pennick","year":"2003"},{"key":"ref33","series-title":"Drug Metab Dispos","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003"},{"key":"ref34","series-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous-to-oral dose escalation regimens","volume":"46","author":"Purkins","year":"2002"},{"key":"ref35","series-title":"J Clin Microbiol","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1128\/JCM.41.8.3623-3626.2003","article-title":"Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B agains 448 recent clinical isolates of filamentous fungi","volume":"41","author":"Diekma","year":"2003"},{"key":"ref36","series-title":"Med Mycol","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/13693780500088416","article-title":"In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi","volume":"43","author":"Gonzalesz","year":"2005"},{"key":"ref37","series-title":"Clin Pharmacokinet","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006"},{"key":"ref38","first-page":"1","article-title":"Voriconazole tablets and voriconazole injection. NDAs 21-266 and 21-267. Background document for the Antiviral Drug Products Advisory Committee Meeting","year":"2001"},{"key":"ref39","article-title":"VFEND [package insert]","year":"2004"}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/68\/10\/ajvr.68.10.1115.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/68\/10\/ajvr.68.10.1115.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/68\/10\/ajvr.68.10.1115.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:16:36Z","timestamp":1741349796000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/68\/10\/ajvr.68.10.1115.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":39,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.2460\/ajvr.68.10.1115","relation":{},"ISSN":["0002-9645"],"issn-type":[{"value":"0002-9645","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}